JP2019520392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520392A5 JP2019520392A5 JP2019500316A JP2019500316A JP2019520392A5 JP 2019520392 A5 JP2019520392 A5 JP 2019520392A5 JP 2019500316 A JP2019500316 A JP 2019500316A JP 2019500316 A JP2019500316 A JP 2019500316A JP 2019520392 A5 JP2019520392 A5 JP 2019520392A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- enzyme
- cgl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 claims 15
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 claims 12
- 102100035429 Cystathionine gamma-lyase Human genes 0.000 claims 10
- 241000288906 Primates Species 0.000 claims 8
- 108090000790 Enzymes Proteins 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 206010011778 Cystinuria Diseases 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000021590 normal diet Nutrition 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359018P | 2016-07-06 | 2016-07-06 | |
| US62/359,018 | 2016-07-06 | ||
| PCT/US2017/040897 WO2018009663A1 (en) | 2016-07-06 | 2017-07-06 | Human-enzyme mediated depletion of cystine for treating patients with cystinuria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520392A JP2019520392A (ja) | 2019-07-18 |
| JP2019520392A5 true JP2019520392A5 (enExample) | 2020-07-02 |
Family
ID=60892921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500316A Ceased JP2019520392A (ja) | 2016-07-06 | 2017-07-06 | ヒト酵素媒介性シスチン枯渇 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180008681A1 (enExample) |
| EP (1) | EP3481425A4 (enExample) |
| JP (1) | JP2019520392A (enExample) |
| KR (1) | KR20190026813A (enExample) |
| CN (1) | CN109562178A (enExample) |
| AU (1) | AU2017291842A1 (enExample) |
| BR (1) | BR112019000215A2 (enExample) |
| CA (1) | CA3028771A1 (enExample) |
| IL (1) | IL263997A (enExample) |
| MX (1) | MX383505B (enExample) |
| WO (1) | WO2018009663A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2788689C (en) | 2010-02-04 | 2019-07-02 | The Board Of Regents Of The University Of Texas System | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof |
| AU2014312159B2 (en) | 2013-08-29 | 2019-02-28 | Board Of Regents, The University Of Texas System | Engineered primate L-methioninase for therapeutic purposes |
| KR102269209B1 (ko) | 2013-08-29 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소 |
| US10865403B2 (en) | 2017-05-12 | 2020-12-15 | Board Of Regents, The University Of Texas System | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
| CA3060988A1 (en) | 2017-05-12 | 2018-11-15 | Board Of Regents, The University Of Texas System | Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria |
| MX2021004754A (es) | 2018-10-26 | 2021-06-08 | Univ Texas | Enzimas de degradacion de cistina/cisteina de primates modificadas por ingenieria genetica para usos terapeuticos. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20060275279A1 (en) | 2005-06-06 | 2006-12-07 | Rozzell J D | Methods for dissolving cystine stones and reducing cystine in urine |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| SI2506857T1 (en) * | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| AU2014312159B2 (en) * | 2013-08-29 | 2019-02-28 | Board Of Regents, The University Of Texas System | Engineered primate L-methioninase for therapeutic purposes |
| KR102269209B1 (ko) | 2013-08-29 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소 |
-
2017
- 2017-07-06 US US15/643,436 patent/US20180008681A1/en not_active Abandoned
- 2017-07-06 CA CA3028771A patent/CA3028771A1/en not_active Abandoned
- 2017-07-06 AU AU2017291842A patent/AU2017291842A1/en not_active Abandoned
- 2017-07-06 CN CN201780041950.0A patent/CN109562178A/zh active Pending
- 2017-07-06 MX MX2019000235A patent/MX383505B/es unknown
- 2017-07-06 JP JP2019500316A patent/JP2019520392A/ja not_active Ceased
- 2017-07-06 EP EP17824888.6A patent/EP3481425A4/en not_active Withdrawn
- 2017-07-06 BR BR112019000215-4A patent/BR112019000215A2/pt not_active Application Discontinuation
- 2017-07-06 KR KR1020197003180A patent/KR20190026813A/ko not_active Withdrawn
- 2017-07-06 WO PCT/US2017/040897 patent/WO2018009663A1/en not_active Ceased
-
2018
- 2018-12-27 IL IL263997A patent/IL263997A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019194251A5 (enExample) | ||
| JP2020203894A5 (enExample) | ||
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2017501977A5 (enExample) | ||
| JP2016533753A5 (enExample) | ||
| JP2014526441A5 (enExample) | ||
| JP2011526303A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2008530245A5 (enExample) | ||
| JP2013515057A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| JP2010520758A5 (enExample) | ||
| CN1655675A (zh) | 利用三叶肽的联合治疗 | |
| JP2023514452A5 (enExample) | ||
| JP2020519278A5 (enExample) | ||
| JP2020530282A5 (enExample) | ||
| JP5981141B2 (ja) | 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 | |
| RU2009104749A (ru) | Рекомбинантные белки, подобные человеческому интреферону | |
| JP2020515283A5 (enExample) | ||
| JP2025519475A5 (enExample) | ||
| JP2019534242A5 (enExample) | ||
| JP2007516214A5 (enExample) | ||
| CN116157140A (zh) | 具有肾酶促效剂活性的稳定胜肽 | |
| CN101671390A (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |